Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) released updated clinical findings for its gene therapy candidate RP-A501, targeting Danon disease, following an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA